Restructuring And mRNA Advances Will Boost Global Prospects

Shared on01 May 25
Fair value Decreased 49%

Shared on24 Apr 25
Fair value Decreased 3.10%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.94%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 89%

AnalystConsensusTarget has decreased revenue growth from -5.4% to -4.8%.